 ROCKVILLE, MD, Nov. 30, 2020 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that 25 million in milestones have been achieved under its exclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte as INCMGA0012. The milestones were triggered by clinical and regulatory activities related to the further advancement of the molecule, including the recent initiation of POD1UM-303, Incytes Phase 3 global study in patients with metastatic squamous cell anal carcinoma SCAC. 